Nephrotic syndrome
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Nephrotic syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code N04.9 in Kidney & Renal, Nephrotic syndrome (also termed Disorder or Syndrome) requires strict blood pressure/glycemic in Nephrotic syndrome (N04.9: control) so specialists can calibrate treatment intensity against Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome (N04.9: (uACR)) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry N04.9: Nephrotic syndrome is managed within Kidney & Renal (aka Disorder).
- 3 Typical cash cost range: Differential triage of Nephrotic syndrome (N04.9) utilizes strict blood pressure/glycemic in Nephrotic syndrome (N04.9: control).
- 4 Top reported side effects / signs: Objective lab/clinical target for Nephrotic syndrome: Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome (N04.9: (uACR)) (< 15 mg/g (< 30 mg/g normal) (N04.9)) and Serum Potassium, Bicarbonate in Nephrotic syndrome (N04.9: & Phosphorus).
Ask our AI Specialists anything about Nephrotic syndrome
What Is Nephrotic syndrome?
Cataloged under federal diagnostic code N04.9 in Kidney & Renal, Nephrotic syndrome (also termed Disorder or Syndrome) requires strict blood pressure/glycemic in Nephrotic syndrome (N04.9: control) so specialists can calibrate treatment intensity against Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome (N04.9: (uACR)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Nephrotic syndrome (ICD-10 N04.9) is driven by impaired nephron solute/acid-base in Nephrotic syndrome (N04.9: clearance); specialists in Chronic Kidney Disease & Electrolytes monitor Serum Potassium, Bicarbonate in Nephrotic syndrome (N04.9: & Phosphorus) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Nephrotic syndrome (N04.9): fluid retention in in Nephrotic syndrome (N04.9: ankles, hands, or)
- • Secondary Nephrotic syndrome clinical sign: fatigue, muscle cramps, in Nephrotic syndrome (N04.9: metallic taste, or)
- • Symptom flares in Nephrotic syndrome correlating with Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome (N04.9: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (N04.9)
- • Functional kidney & renal impact requiring strict blood pressure/glycemic in Nephrotic syndrome (N04.9: control) evaluation (N04.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Nephrotic syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N04.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome (N04.9: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N04.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Nephrotic syndrome (N04.9: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Nephrotic syndrome (N04.9: Cystatin C)) | >= 90 mL/min/1.73m2 (N04.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nephrotic syndrome
Treatment selection for Nephrotic syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nephrotic syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use: What a 257-Participant Study Found In participants with T2D and CKD, consistent benefits of semaglutide on major kidney outcomes, MACE, and all-cause mortality were observed regardless of baseline MRA use. Diabetes care • 2025-11-01 • Randomized Controlled Trial | N = 257 | 93/100 | PMID 40730031 ↗ |
| Can This Approach Help? Inside the Latest Research on Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, We were unable to conclude that lamotrigine is non-inferior to mexiletine; however, improvements in all outcome measures from baseline were similar between lamotrigine and mexiletine. The Lancet. Neurology • 2024-10-15 • Phase III Randomized Trial | N = 30 | 88/100 | PMID 39304240 ↗ |
| Can This Approach Help? Inside the Latest Research on Skeletal muscle adaptation to home-based exercise in chronic kidney NEW & NOTEWORTHY This study investigates the impact of a home-based, video-monitored 12-wk exercise program, consisting of both endurance and resistance exercise, on skeletal muscle structural remodeling in persons with... American journal of physiology. Renal physiology • 2026-11-01 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 42932910 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine Modeling for the Iminosugar Body weight, disease status, and kidney function were shown to influence exposure, with dose adaptation only required in patients with kidney function impairment, as body weight and disease status had limited impact. Journal of clinical pharmacology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42473895 ↗ |
Nephrotic syndrome Patient Community & “People Like Me” Threads
Filter Nephrotic syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.